Search 

Based in Toronto, Canada, DRI Capital Inc. is a life sciences industry-focused investment management firm with over US$2 billion under management that purchases drug royalties from universities, inventors, research institutes and pharmaceutical and biotechnology companies.  DRI Capital closed Drug Royalty II in April, 2010 with US$701 million in equity capital commitments, and a Co-Investment Fund in December, 2010 with an additional US$225 million in equity capital commitments.  Investors in Drug Royalty II and the Co-Investment Fund include corporate entities, public pension plans, 501(c)(3) entities, family offices and a sovereign wealth fund. Royalties recently acquired by DRI’s funds include those on Johnson and Johnson’s Remicade, Amgen and Pfizer’s Enbrel, Kyowa Kirin’s Regpara, and Biogen Idec and Elan’s Tysabri. 

HealthCare Royalty Partners is a global healthcare investment firm with $1.5 billion in assets under management. Launched in 2007 by Founding Managing Directors Gregory B. Brown, M.D., Todd C. Davis and Clarke B. Futch, HC Royalty specializes in making structured investments in commercial-stage healthcare companies and products. Our deep experience, broad and flexible investment platform and proven track record set HC Royalty apart from other firms.

We closed on our first fund, HealthCare Royalty Partners, L.P., in July 2008 with over $500 million in capital. At closing this represented one of the largest inaugural healthcare-focused funds ever raised. In December 2011, we closed the largest private equity fund dedicated to healthcare royalty investments, HealthCare Royalty Partners II, L.P. and an affiliated fund, with $1 billion in capital. Our world-class list of investors consists of public and corporate pension funds, financial institutions, insurance companies, funds-of-funds and university endowments.

Our broad-based internal team has deep investment skills, as well as financial, legal and operational expertise. Collectively, these individuals possess over 100 years of healthcare and financial experience specifically in principal investing, structured finance, healthcare industry senior management, Wall Street research, healthcare industry consulting, and scientific and clinical advisory work

Founded in 2007, HealthCare Royalty Partners is a global healthcare investment firm with over USD 1.5 billion of capital under management. The Firm specializes in structured financing solutions for the life sciences industry.

Karolinska Development aims to create value for investors, patients, and researchers by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.

Today, the portfolio consists of 35 projects, of which 14 are pharmaceuticals in clinical development, 7 in phase I and 7 in phase II

In the active portfolio, Karolinska Development has four projects in oncology, whereof three in clinical development, four clinical development programs in skin disease and wound healing, three projects in women’s health, two in infection, two in CVD, CNS and inflammation respectively and one in opthalmology. Furthermore, 10 technology programs in the areas of implants, diagnostics, formulation and medical equipment. Several are open for licensing and co-development discussions.

We are also looking for breakthrough investment opportunities in the areas of Life Sciences (pharma/biotech, medtech)